UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster

Guirakhoo, Farshad; Wang, Shixia; Wang, Chang Yi; Kuo, Hui Kai; Peng, Wen Jiun; Liu, Hope; Wang, Lixia; ... Goldblatt, David; + view all (2022) High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster. The Journal of Infectious Diseases , 226 (8) pp. 1401-1406. 10.1093/infdis/jiac241. Green open access

[thumbnail of Goldblatt_jiac241.pdf]
Preview
Text
Goldblatt_jiac241.pdf

Download (661kB) | Preview

Abstract

The highly transmissible Omicron variant has caused high rates of breakthrough infections in those previously vaccinated with ancestral strain COVID-19 vaccines. Here, we demonstrate that a booster dose of UB-612 vaccine candidate delivered 7-9 months after primary vaccination increased neutralizing antibody levels by 131-, 61- and 49-fold against ancestral SARS-CoV-2, Omicron BA.1, and BA.2 variants, respectively. Based on the RBD protein-binding antibody responses, the UB-612 third dose booster may lead to an estimated ∼95% efficacy against symptomatic COVID-19 caused by the ancestral strain. Our results support UB-612 as a potential potent booster against current and emerging SARS-CoV-2 variants.

Type: Article
Title: High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1093/infdis/jiac241
Publisher version: https://doi.org/10.1093/infdis/jiac241
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: COVID-19, Omicron, SARS-CoV-2, booster, clinical trial, neutralizing antibody, receptor binding domain, subunit, vaccine, variant
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10150881
Downloads since deposit
912Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item